Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Yinjia (Shanghai) Biomedical Technology

Request full access

Protein R&D for biomedical and life sciences

ChinaFounded 2020Marketing

About Yinjia (Shanghai) Biomedical Technology

Yinjia (Shanghai) Biomedical Technology Co., Ltd. is a protein technology research and development company established in November 2020. The company's founder is Dr. Wu Yifei, who serves as Chairman and CEO.

Yinjia focuses on the application of proteins in biomedicine and other life science fields. It has developed a protein R&D platform that utilizes computer simulation, artificial intelligence, and Cell-Free Protein Synthesis (CFPS) technologies. The company produces high-quality protein-based biomaterials and reagents for applications such as early cancer diagnosis, new drug development, and personalized medication guidance. Its product portfolio includes nearly 200 high-end protein raw materials and quality control testing reagents for therapeutic biologics. These products cover frontier fields like cell and gene therapy (CGT), mRNA and circRNA vaccines, molecular diagnostics, and new anti-tumor drugs. Specific offerings mentioned include Vaccinia Capping Enzyme, 2'-O-methyltransferase, and T7 RNA Polymerase V2, which are produced using E. coli expression systems.

The company operates on a B2B model, providing its products to pharmaceutical companies, innovative drug developers, and diagnostic companies to support their research and development efforts. Yinjia has established laboratories and GMP pilot production platforms in Shanghai, Suzhou, and Beijing. Strategic partnerships are a key part of its growth strategy. In 2021, Yinjia signed a deal with US biotech firm IsoPlexis to advance a proteomics data analysis platform for monitoring therapeutic effects on tumor patients. In 2023, it partnered with Porton Advanced Solutions to develop core protein raw materials and quality control reagents for the CGT sector.

Yinjia has successfully completed multiple funding rounds. It secured tens of millions of yuan in a seed round in January 2021 from investors including CDH Venture and Growth Capital Fund. This was followed by a Pre-A round in July 2021, led by Gaorong Capital, which also raised tens of millions of yuan. In December 2022, the company completed a Series A round of over CNY 100 million (approximately $14M), led by CMB International. Other notable investors across its funding stages include InnoPinnacle and Shanghai Furong Investment. These funds have been allocated towards talent recruitment, expanding production capacity, enhancing its protein optimization platform, and advancing global collaborations.

Source: Dealroom company data

At a glance

Status
Operational
Open positions
None listed
Dealroom signal
19.0/100
Industry
Marketing
Sector
Hard Tech
Business model
Manufacturing
Client focus
B2B
Links
Website

Funding history

1 recorded event

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Jan 2023 $14M $55M InnoPinnacle Fund · CMB International ↗
Showing the latest 1 of 1 recorded eventsBook a demo for the full funding history →

Growth signals

Yinjia (Shanghai) Biomedical Technology website traffic

Latest recorded traffic for Yinjia (Shanghai) Biomedical Technology is 230 monthly website visits, up 76.9% over the last three months.

Latest monthly visits230 3-month web change+76.9%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Yinjia (Shanghai) Biomedical Technology in its local ecosystem

Live from Dealroom

The Yinjia (Shanghai) Biomedical Technology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

5 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A2 investors entered at this stage

  • CMB International
  • InnoPinnacle Fund

Other known investors3 additional known investors

Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇨🇳 China HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Yinjia (Shanghai) Biomedical Technology on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Yinjia (Shanghai) Biomedical Technology’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.